AstraZeneca's Lynparza, armed with new FDA nod, aims to regain share from Tesaro's Zejula
admin 18th August 2017 Uncategorised 0Sorry, Tesaro. Lynparza can now fight back. The AstraZeneca drug—now shared with Merck & Co.—won its new, broader approval in ovarian cancer, putting it on more even footing in its race with Tesaro’s recent launch, Zejula.
More: AstraZeneca's Lynparza, armed with new FDA nod, aims to regain share from Tesaro's Zejula
Source: fierce